forum

LAURUSLABS Share Price Target

Laurus Labs Ltd.
Sector: Pharmaceuticals and health care
... Read more
LAURUSLABS Share Price *
341.1 -0.15 (-0.04%)
* (quote may be delayed)
LAURUSLABS Share Price Forecast - Consensus
No. of reports in last year
9
No. of analysts
3
Average Consensus Forecast
474.22
Consensus Potential
27.66%

LAURUSLABS Share Price Target - Broker Reports - 2019

HDFC Securities
5-Aug-19
Price @ Call: 319.09
Target: 471
BUY
We maintain a BUY on Laurus despite poor operational performance in 1QFY20. After adjusting for lack of scale up in ARV APIs and buoyancy in formulation segment, we have cut our FY20/21E numbers by 5-8% to arrive at a TP of Rs 470/sh (18x FY21E EPS).Laurus is sitting on ~40% underutilized gross block (~Rs 0.9bn) spread across formulations, CRAMS and API segments. With a sharp jump witnessed in formulations and higher visibility of CRAMS orders for FY20, we are confident that the operating/ financial leverage story will unfold from FY20. Assuming formulations revenues/ EBITDA at US$ 85/ 25mn in FY21E, earnings are likely to grow 2.5x over FY19-21E. With all four ARV formulation approvals (TLD, TLE 400, TLE 600, TEE) in place by 1HFY21, addressing >US$ 1.2bn opportunity, the estimates could be breached easily. Maintain BUY.
... Read more

HDFC Securities
17-Jul-19
Price @ Call: 347.45
Target: 515
BUY
Laurus has a high visibility on the offtake in formulations to continue over FY20 with orders in hand for third-party contracts in EU, 3 approvals in the US, and supplies to GF. It expects approvals for TLE/TEE in CY19. With 8-10 yearly ANDA filings, Laurus is likely to achieve a similar no. of approvals, which will boost US revenues. On the margins front, ramp up in formulations will drive gross margin and oplev. We expect a 14/38/63% revenue/EBITDA/PAT CAGR over FY19-21E (low base). Maintain BUY with a TP of Rs 515 (18x FY21E EPS).
... Read more

Kotak Securities
1-Jul-19
Price @ Call: 346.52
Target: 430
BUY
We expect strong volume growth in oncology and other API segments, given the ongoing supply issues in the API industry. We also expect continued growth in other segments, particularly synthesis, which should grow at 25% CAGR from FY19-21. We continue to see value in the stock, with the recent ARV formulation supplies to Global Fund and strong ramp-up in synthesis providing visibility on growth, given pressures in EFV API. BUY; fair value Rs.430, based on ~15X FY21E EPS.
... Read more

Motilal Oswal
6-May-19
Price @ Call: 397.85
Target: 470
BUY

HDFC Securities
26-Apr-19
Price @ Call: 388.2
Target: 417
BUY

Motilal Oswal
11-Apr-19
Price @ Call: 404.5
Target: 470
BUY

HDFC Securities
30-Mar-19
Price @ Call: 407.96
Target: 535
BUY

HDFC Securities
6-Feb-19
Price @ Call: 351.2
Target: 480
BUY

HDFC Securities
10-Jan-19
Price @ Call: 373.91
Target: 480
BUY

LAURUSLABS Share Price Target - Broker Reports - 2018

Motilal Oswal
6-Aug-18
Price @ Call: 469
Target: 552
BUY

Motilal Oswal
11-May-18
Price @ Call: 485.8
Target: 586
BUY

Motilal Oswal
5-Mar-18
Price @ Call: 533.7
Target: 613
BUY

Motilal Oswal
30-Jan-18
Price @ Call: 515.54
Target: 613
BUY

Motilal Oswal
16-Jan-18
Price @ Call: 538.09
Target: 651
BUY

LAURUSLABS Share Price Target - Broker Reports - 2017

HDFC Securities
18-Dec-17
Price @ Call: 521.5
Target: 633
BUY

Kotak Securities
1-Sep-17
Price @ Call: 526
Target: 570
BUY

  • LAURUSLABS - Share Price Target Potential

    keyboard_arrow_down
    BrokerageTargetPotential
    HDFC Securities47127.55%
    Kotak Securities43020.64%
    Motilal Oswal47027.39%